alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 33 studies by Lee J (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Simultaneous Aerobic Exercise and Memory Training Program in Older Adults with Subjective Memory Impairments

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01

These findings indicate that a 4-week simultaneous memory training and aerobic exercise program is sufficient to improve memory, attention, and reasoning abilities in older adults. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source

The Effect of a Virtual Reality-Based Intervention Program on Cognition in Older Adults with Mild Cognitive Impairment: A Randomized Control Trial

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Journal of clinical medicine 2020-04-29

This study aimed to investigate the association between a virtual reality (VR) intervention program and cognitive, brain and physical functions in high-risk older adults. 4 key findings →

Design: randomized controlled trial Participants: 68 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Hospice Utilization in the United States: A Prospective Cohort Study Comparing Cancer and Noncancer Deaths

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Journal of the American Geriatrics Society 2019-12-27

Extrapolating results to the US population, we estimate that annually nearly a million individuals who are likely eligible for hospice die without its services. 4 key findings →

Design: cohort study Participants: 1,209 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurology 2023-10-03

This trial tested an antibody targeting tau tangles rather than amyloid plaques, in people with mild-to-moderate Alzheimer's. It slowed decline on one cognitive test by 42% compared with placebo, the first time an anti-tau antibody showed any cognitive benefit, but it did not help with daily-function scores, overall dementia staging (CDR-SB), or the MMSE, and it did not reduce tangle buildup seen on tau brain scans. 5 key findings →

Design: phase-2-trial Participants: 272 Evidence: preliminary

Full summary, score breakdown and related studies → Original source

A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Clinical nutrition (Edinburgh, Scotland) 2011-01-08

Homocysteine lowering in dementia patients did not significantly reduce global cognitive decline. 3 key findings →

Participants: 140 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Acta neuropathologica communications 2019-11-06

To date, the development of disease-modifying therapies for Alzheimer's disease (AD) has largely focused on the removal of amyloid beta Aβ fragments from the CNS. 4 key findings →

Participants: 59 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Retinal image analytics detects white matter hyperintensities in healthy adults

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Annals of clinical and translational neurology 2018-11-15

We developed a robust algorithm to automatically evaluate retinal fundus image that can identify subjects with high WMH burden. 3 key findings →

Design: cross-sectional Participants: 180 Evidence: low

Full summary, score breakdown and related studies → Original source

Variation in use of antipsychotic medications in nursing homes in the United States: A systematic review

✓ Peer-reviewed alzhub usefulness score 55 out of 100. BMC geriatrics 2017-01-26

Variation in use of APMs in U.S. nursing homes based upon facility characteristics exemplifies the need for a more systematic protocol guiding the use of these medications, along with heightened regulatory policies and enforcement. 2 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Molecular neurodegeneration 2024-05-15

Alzheimer's disease (AD), the most common form of dementia, remains challenging to understand and treat despite decades of research and clinical investigation. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The effects of low-dose radiation therapy in patients with mild-to-moderate Alzheimer's dementia: an interim analysis of a pilot study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Radiation oncology journal 2023-06-26

One of the five patients with AD treated with LDRT experienced a temporary improvement in SNSB-II. 1 key finding →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2003-03-24

L-Arginine is the only endogenous nitrogen-containing substrate of NO synthase (NOS), and it thus governs the production of NO during nervous system development as well as in disease states such as stroke, multiple sclerosis, Parkinson's disease, and HIV dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Journal of biological chemistry 2008-02-13

Accumulation of extracellular amyloid beta peptide (Abeta), generated from amyloid precursor protein (APP) processing by beta- and gamma-secretases, is toxic to neurons and is central to the pathogenesis of Alzheimer disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neuroscience letters 2010-07-27

Obesity is a growing global health problem that contributes to diabetes, hypertension, cardiovascular diseases, dementia, and cancer. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Interdisciplinary palliative care for people with advanced Parkinson's disease: a view from the home

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Annals of palliative medicine 2019-10-14

As our population ages, therapies increase, and the number of individuals living with advanced PD and related disorders grows, so too does the imperative to recognize and address the palliative care needs of such patients and families. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

18F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Yonsei medical journal 2022-03-01

The results of the present study suggest that increased 18 F-THK5351 uptake might be a useful predictor of poor prognosis among Aβ- aMCI patients, which might be associated with increased neuroinflammation (ClinicalTrials.gov NCT02656498). 3 key findings →

Design: clinical trial Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

✓ Peer-reviewed alzhub usefulness score 38 out of 100. The Journal of pharmacology and experimental therapeutics 2020-06-03

Deposition of hyperphosphorylated and aggregated tau protein in the central nervous system is characteristic of Alzheimer disease and other tauopathies. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed